Lexicon Pharmaceuticals, Inc. (LXRX) Stock Score, Valuation & Financial Research
Lexicon Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 18/100.
Quick answer for LXRX
Lexicon Pharmaceuticals, Inc. currently has a Wall Street Score of 18/100. The stored market price is $2.02. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Lexicon Pharmaceuticals, Inc. does
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
LXRX financial snapshot
- Wall Street Score:
- 18/100
- Current price:
- $2.02
- Market capitalization:
- $897.3M
- Revenue:
- $69.6M
- Net income:
- $-26.1M
- Free cash flow:
- $-67.9M
- Cash:
- $38.1M
- Total debt:
- $57.7M
- EPS:
- -0.14
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 41/100
What stands out
- Reported year-over-year revenue growth is +0.4%.
- Free cash flow is $-67.9M, showing cash burn in the current stored period.
- The balance sheet shows $38.1M of cash versus $57.7M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research LXRX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.